カレントテラピー　36-4　サンプル page 32/38

このページは カレントテラピー　36-4　サンプル の電子ブックに掲載されている32ページの概要です。
秒後に電子ブックの対象ページへ移動します。
「電子ブックを開く」をクリックすると今すぐ対象ページへ移動します。

概要：
カレントテラピー　36-4　サンプル

82 Current Therapy 2018 Vol.36 No.4388Heart Failure（RELAX -AHF）Investigators：Serelaxin,recombinant human relaxin-2, for treatment of acute heartfailure（RELAX-AHF）：a randomised, placebo-controlledtrial. Lancet 381：29-39, 20133）Teerlink JR, Voors AA, Ponikowski P, et al：Serelaxin inaddition to standard therapy in acute heart failure：rationaleand design of the RELAX-AHF-2 study. Eur J Heart Fail19：800-809, 20174）Packer M, Califf RM, Konstam MA, et al：Comparison ofomapatrilat and enalapril in patients with chronic heart failure：the Omapatrilat Versus Enalapril Randomized Trial ofUtility in Reducing Events（OVERTURE）. Circulation 106：920-926, 20025）McMurray JJ, Packer M, Desai AS, et al；PARADIGM-HFInvestigators and Committees：Angiotensin-neprilysin inhibitionversus enalapril in heart failure. N Engl J Med 371：993-1004, 20146）Solomon SD, Rizkala AR, Gong J, et al：Angiotensin ReceptorNeprilysin Inhibition in Heart Failure With PreservedEjection Fraction：Rationale and Design of the PARAGONHFTrial. JACC Heart Fail 5：471-482, 20177）S w e d b e r g K , K o m a j d a M , B o h m M , e t a l；S H I F TInvestigators：Ivabradine and outcomes in chronic heart failure（SHIFT）：a randomised placebo -controlled study.Lancet 376：875-885, 20108）B o h m M , S w e d b e r g K , K o m a j d a M , e t a l；S H I F TInvestigators：Heart rate as a risk factor in chronic heartfailure（SHIFT）：the association between heart rate andoutcomes in a randomised placebo-controlled trial. Lancet376：886-894, 20109）Zinman B, Wanner C, Lachin JM, et al；EMPA - REGOUTCOME Investigators：Empagliflozin, CardiovascularOutcomes, and Mortality in Type 2 Diabetes. N Engl J Med373：2117-2128, 201510）Neal B, Perkovic V, Mahaffey KW, et al；CANVAS ProgramCollaborative Group：Canagliflozin and Cardiovascular andRenal Events in Type 2 Diabetes. N Engl J Med 377：644-657, 201711）Multicenter trial to evaluate the effect of dapagliflozin on theincidence of cardiovascular events（DECLARE -TIMI58）（https://clinicaltrials.gov/ct2/show/NCT01730534）12）Nakagaito M, Joho S, Ushijima R, et al：SuccessfulWithdrawal from Dobutamine by Canagliflozin in a DiabeticPatient with Stage D Heart Failure. Int Heart J 58：978-981,201713）Study to Evaluate the Effect of Dapagliflozin on theIncidence of Worsening Heart Failure or CardiovascularDeath in Patients With Chronic Heart Failure（Dapa-HF）.（https://clinicaltrials.gov/ct2/show/NCT03036124）14）Butler J, Hamo CE, Filippatos G, et al；EMPEROR TrialsProgram：The potential role and rationale for treatment ofheart failure with sodium-glucose co-transporter 2 inhibitors.Eur J Heart Fail 19：1390-1400, 201715）Teerlink JR, Felker GM, McMurray JJ, et al；COSMIC-HFInvestigators：Chronic Oral Study of Myosin Activation toIncrease Contractility in Heart Failure（COSMIC -HF）：aphase 2, pharmacokinetic, randomised, placebo -controlledtrial. Lancet 388：2895-2903, 201616）V o o r s A A , D u n g e n H D , S e n n i M , e t a l：S a f e t y a n dTolerability of Neladenoson Bialanate, a Novel Oral PartialAdenosine A1 Receptor Agonist, in Patients With ChronicHeart Failure. J Clin Pharmacol 57：440-451, 201717）Armstrong PW, Roessig L, Patel MJ, et al：A Multicenter,Randomized, Double-Blind, Placebo-Controlled Trial of theEfficacy and Safety of the Oral Soluble Guanylate CyclaseStimulator：The VICTORIA Trial. JACC Heart Fail 6：96-104, 201718）Van Tassell BW, Buckley LF, Carbone S, et al：Interleukin-1blockade in heart failure with preserved ejection fraction：rationale and design of the Diastolic Heart Failure AnakinraResponse Trial 2（D -HART2）. Clin Cardiol 40：626-632,2017